Holen Sie sich die Stockscreener-App
10.08
2.44%
0.24
Handel nachbörslich:
9.90
-0.18
-1.79%
Schlusskurs vom Vortag:
$9.84
Offen:
$10.1
24-Stunden-Volumen:
298.28K
Relative Volume:
7.56
Marktkapitalisierung:
$758.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.67%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.70
$10.51
1-Wochen-Bereich:
$8.79
$10.51
52-Wochen-Spanne:
$8.70
$12.50
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Firmenname
Bridgebio Oncology Therapeutics Inc
Sektor
Branche
Telefon
857 702 0377
Adresse
C/O CORMORANT ASSET MANAGEMENT, LP, BOSTON
Vergleichen Sie BBOT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
10.08 | 758.70M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Eingeleitet | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc Aktie (BBOT) Neueste Nachrichten
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com
Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target - MarketScreener
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - MSN
BridgeBio Oncology Therapeutics shares rise 4.57% after-hours after announcing participation in September investor conferences. - AInvest
BBOT to Participate in Upcoming September Investor Healthcare Conferences - The Manila Times
BBOT to Participate in Upcoming September Investor Healthcare Conferences - GlobeNewswire Inc.
BridgeBio's Strategy To Unleash The Full Potential Of RASDrugging The Undruggable - RTTNews
BridgeBio Oncology Therapeutics shares rise 11.34% premarket after Wedbush initiates coverage. - AInvest
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely - Yahoo Finance
We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth - simplywall.st
BridgeBio Oncology Therapeutics shares rise 1.17% intraday after Piper Sandler initiates coverage. - AInvest
Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target - MarketScreener
BridgeBio Oncology initiated with an Overweight at Piper Sandler - TipRanks
Bridgebio Oncology Therapeutics, Inc. shares rise 2.12% intraday after Helix Acquisition Corp. II retains more than 60% of trust account. - AInvest
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating - Investing.com
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - MarketScreener
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer - Business Wire
Helix Acquisition Corp. II Clears SEC Hurdle for BBOT Business Combination - Stock Titan
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
Boston SPAC picks biotech to take public - The Business Journals
Seven biotech spinouts to watch out for in 2025 - Labiotech.eu
BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC - OncLive
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS - Business Wire
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRASG12C Mutant Tumors - BioSpace
Unnatural Products Announces BridgeBio Exercises Option to - GlobeNewswire
BridgeBio Oncology Therapeutics Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - MarketScreener
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Business Wire
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer - Business Wire
BridgeBio launches another new company, GondolaBio - The Pharma Letter
BridgeBio forms another offshoot with $300M in commitments - Endpoints News
How Computer-Aided Drug Discovery Is Leading to Revolutionary Cancer Treatment - Tech Briefs
Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout - Fierce Biotech
BridgeBio Pharma spins out cancer-focused unit with three drugs, $200 millionSan Francisco Business Times - The Business Journals
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner - GlobeNewswire
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn - GlobeNewswire
BridgeBio Acquires Remaining Stake in Eidos to Tune of $175 Million - BioSpace
BridgeBio - Crunchbase
Finanzdaten der Bridgebio Oncology Therapeutics Inc-Aktie (BBOT)
Es liegen keine Finanzdaten für Bridgebio Oncology Therapeutics Inc (BBOT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):